Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTIC-2: Ticagrelor vs Prasugrel in Prior Myocardial Infarction
NCT03387826Phase 4Completed
- Sponsor
- Attikon University Hospital
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ticagrelor and prasugrel in myocardial infarction (MI) (2 arms), sponsored by Attikon University Hospital. Primary endpoint: Platelet Reactivity Units at 14 days. Started Jan 2018; status: completed.
02
Drugs
ticagrelorprasugrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT03387826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387826.